EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

CXCL10 and Nrf2-upregulated mesenchymal stem cells reinvigorate T lymphocytes for combating glioblastoma

Jiaji Mao, Jianing Li, Junwei Chen, Qin Wen, Minghui Cao, Fang Zhang, Baoxun Li, Qinyuan Zhang, Zhe Wang, Jingzhong Zhang, Jun Shen iD

Journal for ImmunoTherapy of Cancer · 2023-12 · 11 (12) · e007481

DOI: 10.1136/jitc-2023-007481 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 06.12.2023. Verfasst von Jiaji Mao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Y…. Hauptthemen laut MEDLINE: Glioblastoma, Mesenchymal Stem Cells. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Natural Science Foundation, Key R&D Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lack of tumor-infiltrating T lymphocytes and concurrent T-cell dysfunction have been identified as major contributors to glioblastoma (GBM) immunotherapy resistance. Upregulating CXCL10 in the tumor microenvironment (TME) is a promising immunotherapeutic approach that potentially increases tumor-infiltrating T cells and boosts T-cell activity but is lacking effective delivery methods.

Methods

In this study, mesenchymal stem cells (MSCs) were transduced with a recombinant lentivirus encoding Cxcl10 , Nrf2 (an anti-apoptosis gene), and a ferritin heavy chain ( Fth ) reporter gene in order to increase their CXCL10 secretion, TME survival, and MRI visibility. Using FTH-MRI guidance, these cells were injected into the tumor periphery of orthotopic GL261 and CT2A GBMs in mice. Combination therapy consisting of CXCL10-Nrf2-FTH-MSC transplantation together with immune checkpoint blockade (ICB) was also performed for CT2A GBMs. Thereafter, in vivo and serial MRI, survival analysis, and histology examinations were conducted to assess the treatments’ efficacy and mechanism.

Results

CXCL10-Nrf2-FTH-MSCs exhibit enhanced T lymphocyte recruitment, oxidative stress tolerance, and iron accumulation. Under in vivo FTH-MRI guidance and monitoring, peritumoral transplantation of CXCL10-Nrf2-FTH-MSCs remarkably inhibited orthotopic GL261 and CT2A tumor growth in C57BL6 mice and prolonged animal survival. While ICB alone demonstrated no therapeutic impact, CXCL10-Nrf2-FTH-MSC transplantation combined with ICB demonstrated an enhanced anticancer effect for CT2A GBMs compared with transplanting it alone. Histology revealed that peritumorally injected CXCL10-Nrf2-FTH-MSCs survived longer in the TME, increased CXCL10 production, and ultimately remodeled the TME by increasing CD8 + T cells, interferon-γ + cytotoxic T lymphocytes (CTLs), GzmB + CTLs, and Th1 cells while reducing regulatory T cells (Tregs), exhausted CD8 + and exhausted CD4 + T cells.

Conclusions

MRI-guided peritumoral administration of CXCL10 and Nrf2-overexpressed MSCs can significantly limit GBM growth by revitalizing T lymphocytes within TME. The combination application of CXCL10-Nrf2-FTH-MSC transplantation and ICB therapy presents a potentially effective approach to treating GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaMesenchymal Stem CellsAnimalsMiceCD8-Positive T-LymphocytesMice, Inbred C57BLNF-E2-Related Factor 2Tumor MicroenvironmentChemokine CXCL10

Stichwörter der Autor:innen

brain neoplasmscell engineeringimmunotherapylymphocytes, tumor-infiltratingtumor microenvironment

Substanzen

NF-E2-Related Factor 2Nfe2l2 protein, mouseCxcl10 protein, mouseChemokine CXCL10

Autor:innen und Institutionen

  • Department of Radiology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.
  • The Key Laboratory of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, Jiangsu, China.
  • Department of Radiology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China shenjun@mail.sysu.edu.c…

ORCID-Profile: Jun Shen

Förderung

  • National Natural Science Foundation of China
  • Guangdong Natural Science Foundation
  • Key R&D Program of China

Zitieren

APA

Mao, J., Li, J., Chen, J., Wen, Q., Cao, M., Zhang, F., Li, B., Zhang, Q., Wang, Z., Zhang, J., & Shen, J. (2023). CXCL10 and Nrf2-upregulated mesenchymal stem cells reinvigorate T lymphocytes for combating glioblastoma. Journal for ImmunoTherapy of Cancer, 11(12), e007481. https://doi.org/10.1136/jitc-2023-007481

Vancouver

Mao J, Li J, Chen J, Wen Q, Cao M, Zhang F, et al. CXCL10 and Nrf2-upregulated mesenchymal stem cells reinvigorate T lymphocytes for combating glioblastoma. Journal for ImmunoTherapy of Cancer. 2023;11(12):e007481. doi:10.1136/jitc-2023-007481

BibTeX
@article{Mao2023,
  author = {Mao, Jiaji and Li, Jianing and Chen, Junwei and Wen, Qin and Cao, Minghui and Zhang, Fang and Li, Baoxun and Zhang, Qinyuan and Wang, Zhe and Zhang, Jingzhong and Shen, Jun},
  title = {CXCL10 and Nrf2-upregulated mesenchymal stem cells reinvigorate T lymphocytes for combating glioblastoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {12},
  pages = {e007481},
  doi = {10.1136/jitc-2023-007481}
}
Kostenlos starten →